Results 111 to 120 of about 186,761 (273)

Carbon Footprint of Antibody‐Based Drugs and Biologics Using Hybrid Life Cycle Assessment

Clinical Pharmacology &Therapeutics, EarlyView.
Life cycle assessment of monoclonal antibodies. Biological engineering has emerged since the 1980s as one of the most efficient technologies to develop new medicines. The monoclonal antibody platform is the most widely used, representing about 15–20% of drug sales.
Sébastien Taillemite, Martin Fenelon, Marc Scherlinger, Max Piffoux   +3 more
wiley   +1 more source

From Basics to Benchmarks: Evaluating Sample Adequacy, PD‐L1 Expression, and Molecular Profiling in Effusion Samples of Lung Adenocarcinoma

Diagnostic Cytopathology, EarlyView.
ABSTRACT Introduction Lung adenocarcinoma commonly causes malignant pleural effusion (MPE), a condition with poor prognosis and limited treatment options. Pleural effusion specimens offer a minimally invasive source for diagnosis and molecular testing.
Harpreet Virk, Claire Michael, Keri Ann Pfeil, Navid Sadri, Omid Savari, Aparna Harbhajanka   +5 more
wiley   +1 more source

Novel Organelle‐Based Intracellular Immunity With Mechanistic and Therapeutic Implications

Barrier Immunity, EarlyView.
A conceptual framework illustrating how PAMPs/DAMPs initiate barrier, innate, adaptive, and intracellular immune responses, with organelle‐based intracellular immunity serving as a central integrator linking metabolism, inflammatory signaling, and therapeutic interventions to restore immune homeostasis.
Keman Xu, Shih‐Yu Hung, Fatma Saaoud, Ying Shao, Yifan Lu, Juanjuan Liu, Bo Yuan, Haiyan Xiang, Hong Wang, Xiaofeng Yang   +9 more
wiley   +1 more source

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. [PDF]

, 2019
Glioblastoma is the most common primary malignant brain tumor in adults and is associated with poor survival. The Ivy Foundation Early Phase Clinical Trials Consortium conducted a randomized, multi-institution clinical trial to evaluate immune responses ...
Arrillaga-Romany, Isabel C, Butowski, Nicholas A, Clarke, Jennifer L, Cloughesy, Timothy F, Cohen, Adam L, Colman, Howard, Davidson, Tom B, de Groot, John F, Du, Lin, Ellingson, Benjamin M, Gaffey, Sarah C, Hugo, Willy, Kaley, Thomas J, Kawaguchi, Eric S, Lee, Alexander H, Lee, Eudocia Q, Li, Gang, Liau, Linda M, Mellinghoff, Ingo K, Mochizuki, Aaron Y, Nghiemphu, Phioanh L, O'Brien, Barbara J, Orpilla, Joey R, Prins, Robert M, Reardon, David A, Rytlewski, Julie A, Sanders, Catherine M, Wang, Anthony C, Wen, Patrick Y, Yong, William H   +29 more
core  

Standardized Management Pathway to Prevent Acute Rejection After Liver Transplantation Following ICI Therapy for Downstaging HCC

Health Care Science, EarlyView.
Findings indicate that within a standardized clinical pathway integrating structured immunosuppression, therapeutic drug monitoring, and early complication surveillance, liver transplantation after ICI exposure can be performed safely without increased rejection risk.
Ning Wang, Zebin Zhu, Hao Zheng, Can Qi, Xiaodong Yuan, Xuefeng Li, Zhijun Xu, Jiwei Qin, Wei Wu, Jizhou Wang, Ruipeng Song, Zhiyong Guo, Lianxin Liu, Shu‐Geng Zhang, Björn Nashan   +14 more
wiley   +1 more source

Tolerance of Concurrent Adjuvant Radiation Therapy and Pembrolizumab for Triple Negative Breast Cancer: Real Life Experience

Advances in Radiation Oncology
Purpose: The current standard-of-care management of locally advanced triple negative breast cancer (TNBC) is based on neoadjuvant chemo-immunotherapy with pembrolizumab, surgery, radiation therapy (RT), and adjuvant pembrolizumab.
Thais Tison, MD, Pierre Loap, MD, Emilie Arnaud, MD, Kim Cao, MD, Solene Bringer, MD, Manon Kissel, MD, Safia Maaradji, MD, Juliette Mainguene, MD, Jean-Yves Pierga, MD, PhD, Florence Lerebours, MD, Anne Vincent-Salomon, MD, PhD, Mariana Mirabelle, MD, Francois-Clement Bidard, MD, PhD, Delphine Loirat, MD, PhD, Youlia M. Kirova, MD   +14 more
doaj   +1 more source

A case of new-onset vitiligo in a patient on tofacitinib and brief review of paradoxical presentations with other novel targeted therapies [PDF]

, 2020
With recent advancements in the understanding of vitiligo pathogenesis, Janus kinase (JAK) inhibitors have emerged as a promising new treatment modality, but their effects remain incompletely elucidated.
Alikhan, Mujahed, Jogi, Reena, Nguyen, Julie K, Patel, Anisha B, Schlichte, Megan J   +4 more
core  

Deceptive Thyroid Pathologies: Anaplastic Thyroid Carcinoma Mimics and Clinical Implications

Head &Neck, EarlyView.
ABSTRACT Background Beyond follicular‐derived thyroid carcinomas, lymphomas, and metastatic disease, there are rare pathologies of the thyroid gland that represent a challenge. We report patients with unusual malignancies that mimic similar aggressive cancers. Methods Retrospective case series.
David Z. Allen, S. Mohsen Hosseini, Mark Zafereo, Miriam Lango, Elizabeth Gardner Grubbs, Priyanka Iyer, Shreyaskumar R. Patel, Vinod Ravi, Naifa Lamki Busaidy, Rui Jennifer Wang, Michelle D. Williams, Maria E. Cabanillas, Anastasios Maniakas   +12 more
wiley   +1 more source

Disparity in the Markers of Affordability Across Targeted‐ and Immune‐Therapy Drugs Used in Head and Neck Cancers

Head &Neck, EarlyView.
ABSTRACT Background The expanding use of systemic therapies for recurrent and metastatic head and neck cancer has raised major concerns regarding affordability and equitable access, particularly across countries with differing income levels and health financing structures.
Arjun Gurmeet Singh, Labani Kole, Richard Sullivan, Shwetabh Sinha, Rathan Shetty, Poonam Joshi, Sudhir Nair, Sarbani Ghosh Laskar, Kumar Prabhash, Pankaj Chaturvedi   +9 more
wiley   +1 more source

Systemic Treatments for Recurrent or Metastatic Sinonasal Carcinomas: A Retrospective Multicenter Study

Head &Neck, EarlyView.
ABSTRACT Introduction Sinonasal cancers are rare and heterogeneous and pose a therapeutic challenge at an advanced stage due to the lack of data on appropriate systemic management. Methods This retrospective multicenter study analyzed 83 patients with recurrent or metastatic sinonasal carcinomas ineligible for curative treatment, treated in France ...
Marie Degrange, Mathilde Morisseau, Justin Michel, Thibaut Reverdy, Sylvain Morinière, Amaury Daste, Maxime Humbert, Caroline Viala, Pauline Corbaux, Tiffany Darbas, François‐Régis Ferrand, Valentin Favier, Camille Evrard, Diane Evrard, Delphine Farneti, Sarah Betrian‐Lagarde, Victor Sarradin   +16 more
wiley   +1 more source